Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 14th Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Patrick J. McEnany, Chief Executive Officer, will be presenting at Rodman & Renshaw's 14th Annual Healthcare Conference, which is being held on September 10-11, 2012 at The Waldorf=Astoria in New York, NY.
The presentation will occur on Monday, September 10th at 9:05am PT / 12:05pm ET. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
About Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including the treatment of addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, in a Phase II(b) study for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst expects to develop CPP-115 for addiction, epilepsy (initially infantile spasms) and other CNS indications. CPP-109 and CPP-115 have been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted EU medicinal product designation for the treatment of West Syndrome by the European Commission. For more information about Catalyst, go to www.catalystpharma.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: For Further Information Contact: Patrick J. McEnany Catalyst Pharmaceutical Partners Chief Executive Officer (305) 529-2522 email@example.com Melody Carey Rx Communications Group Co-President (917) 322-2571 firstname.lastname@example.org